Pulmonary arterial hypertension (PAH)
- Confirm PAH with specialist evaluation/RHC
- Initial combination therapy is common
- endothelin antagonist + PDE5 inhibitor
- Higher-risk disease → add prostacyclin pathway
- Riociguat replaces—not combines with—PDE5 drug
- Follow risk markers and escalate early
- Treat underlying connective-heart/lung disease
Use at a glance
- Confirm PAH with specialist evaluation/RHC
Treatment options
- Initial combination therapy is common
- endothelin antagonist + PDE5 inhibitor
Other treatment options
- Riociguat replaces—not combines with—PDE5 drug
- Treat underlying connective-heart/lung disease
Monitoring / follow-up
- Higher-risk disease → add prostacyclin pathway
- Follow risk markers and escalate early
Self-check
- Should riociguat be combined with a PDE5 drug?
No—it replaces it. - How is PAH confirmed before treatment?
Specialist evaluation/right-heart catheterization.
Drugs used for this (8)
All clinical uses · Open Pulmonary arterial hypertension (PAH) in the interactive console ↗